(Q36458457)

14 August 2017

title

Chemoprevention of prostate cancer with finasteride. (English)

1 reference

14 August 2017

Edith D Canby-Hagino

1

1 reference

14 August 2017

Timothy C Brand

series ordinal

2

1 reference

14 August 2017

Javier Hernandez

series ordinal

3

1 reference

14 August 2017

Ian M Thompson

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

899-905

1 reference

The influence of finasteride on the development of prostate cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

5alpha-reductase activity in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

International trends and patterns of prostate cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

5 alpha-reductase inhibitors: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Human prostate cancer precursors and pathobiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Long-term effects of finasteride on prostate tissue composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.899

21 January 2018

Identifiers

DOI

10.1517/14656566.7.7.899

1 reference

release_yrd7a6sg7zcjxnd5uvkghb3ma4

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yrd7a6sg7zcjxnd5uvkghb3ma4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference